Nuclear receptors as negative modulators of STAT3 in multiple myeloma

Cell Cycle

Volumn 4, Issue 2, 2005, Pages 242-245

  Li, Hua Wang ^a,b,c   Xiao, Yi Yang ^a   Zhang, Xiaohu ^a   Farrar, William L ^b,c  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NONE   (United States)

Author keywords

Crosstalk; ER; Interleukin 6; Multiple myeloma; Nuclear receptor; PPAR ; STAT3

Indexed keywords

CELL NUCLEUS RECEPTOR; CYTOKINE; ESTROGEN RECEPTOR; INTERLEUKIN 6; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; RECEPTOR PROTEIN; STAT3 PROTEIN; STEROID RECEPTOR; THYROID HORMONE RECEPTOR; TRANSCRIPTION FACTOR; VITAMIN D RECEPTOR;

APOPTOSIS; BONE MARROW; CANCER CELL CULTURE; CANCER GROWTH; CELL GROWTH; CHROMATIN; DNA BINDING; GENE EXPRESSION; HUMAN; IMMUNOPRECIPITATION; MULTIPLE MYELOMA; NONHUMAN; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 25444489843     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (28)

1. Kuehl WM, Bergsagel PL. Multiple myeloma: Evolving genetic events and host interactions. Nat Rev Cancer 2002; 2:175-87.
2. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: Clinical applications. Blood 2004; 104:607-18.
3. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science 2002; 296:1653-5.
4. Lonial S, Waller EK, Simons JW, Heffner Jr LT. Signal transduction and myeloma: New targets, new hope. Cancer Biol Ther 2003; 2:310-9.
5. Darnell Jr JE. STATs and gene regulation. Science 1997; 277:1630-5.
6. Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001; 13:211-7.
7. Levy DE, Lee CK. What does Stat3 do? J Clin Invest 2002; 109:1143-8.
8. Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A. STAT proteins: From normal control of cellular events to tumorigenesis. J Cell Physiol 2003; 197:157-68.
9. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19:2474-88.
10. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell Jr JE. Stat3 as an oncogene. Cell 1999; 98:295-303.
11. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10:105-15.
12. Quintanilla-Martinez L, Kremer M, Specht K, Calzada-Wack J, Nathrath M, Schaich R, Hofler H, Fend F. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol 2003; 162:1449-61.
13. Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K, Hibi M, Hirano T. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med 1999; 189:63-73.
14. + T cells through phosphatidylinositol 3-kinase/Akt signaling pathway. J Immunol 2002; 169:3637-43.
15. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83:841-50.
16. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: Cellular and molecular biology. Endocr Rev 1999; 20:321-44.
17. Westin S, Kurokawa R, Nolte RT, Wisely GB, McInerney EM, Rose DW, Milburn MV, Rosenfeld MG, Glass CK. Interactions controlling the assembly of nuclear-receptor heterodimers and coactivators. Nature 1998; 395:199-202.
18. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clinical Cancer Res 2002; 8:945-54.
19. Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004; 3:950-64.
20. Wang LH, Yang XY, Zhang X, Huang J, Hou J, Li J, Xiong H, Mihalic K, Zhu H, Xiao W, Farrar WL. Transcriptional inactivation of STAT3 by PPAR\gamma\ suppresses IL-6-responsive multiple myeloma cells. Immunity 2004; 20:205-18.
21. Wang LH, Yang XY, Mihalic K, Xiao W, Li D, Farrar WL. Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by coregulator PIAS3. J Biol Chem 2001; 276:31839-44.
22. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004; 10:355-61.
23. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: Complex stories. Nat Rev Cancer 2004; 4:61-70.
24. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor \gamma\ agonists. Lancet Oncol 2004; 5:419-29.
25. Cooke PS, Buchanan DL, Lubahn DB, Cunha GR. Mechanism of estrogen action: Lessons from the estrogen receptor-\alpha\ knockout mouse. Biol Reprod 1998; 59:470-5.
26. Yamamoto T, Matsuda T, Junicho A, Kishi H, Saatcioglu F, Muraguchi A. Cross-talk between signal transducer and activator of transcription 3 and estrogen receptor signaling. FEBS Lett 2000; 486:143-8.
27. Otsuki T, Yamada O, Kurebayashi J, Moriya T, Sakaguchi H, Kunisue H, Yata K, Uno M, Yawata Y, Ueki A. Estrogen receptors in human myeloma cells. Cancer Res 2000; 60:1434-41.
28. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997; 278:1803-5.